Guangzhou LBP Medicine Science & Technology Co Ltd (688393) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangzhou LBP Medicine Science & Technology Co Ltd (688393) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥29.17 Million ≈ $4.27 Million USD) by net assets (CN¥1.20 Billion ≈ $175.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guangzhou LBP Medicine Science & Technology Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Guangzhou LBP Medicine Science & Technology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Guangzhou LBP Medicine Science & Technol total liabilities for a breakdown of total debt and financial obligations.
Guangzhou LBP Medicine Science & Technology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangzhou LBP Medicine Science & Technology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HCK Capital Group Bhd
KLSE:7105
|
-0.121x |
|
Settlebank Corporation
KQ:234340
|
0.049x |
|
Eche Izquierdo
SN:EISA
|
0.071x |
|
Neurogene Inc
NASDAQ:NGNE
|
-0.063x |
|
Echomarketing Co.Ltd
KQ:230360
|
0.049x |
|
IVF Hartmann Holding AG
SW:VBSN
|
0.014x |
|
Motech Industries Co Ltd
TWO:6244
|
0.132x |
|
ABC arbitrage SA
PA:ABCA
|
0.075x |
Annual Cash Flow Conversion Efficiency for Guangzhou LBP Medicine Science & Technology Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Guangzhou LBP Medicine Science & Technology Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 688393 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.23 Billion ≈ $180.24 Million |
CN¥3.54 Million ≈ $518.49K |
0.003x | -79.19% |
| 2023-12-31 | CN¥1.24 Billion ≈ $181.20 Million |
CN¥17.12 Million ≈ $2.51 Million |
0.014x | +73.94% |
| 2022-12-31 | CN¥1.22 Billion ≈ $178.87 Million |
CN¥9.72 Million ≈ $1.42 Million |
0.008x | -83.87% |
| 2021-12-31 | CN¥1.21 Billion ≈ $177.02 Million |
CN¥59.61 Million ≈ $8.72 Million |
0.049x | -37.07% |
| 2020-12-31 | CN¥1.17 Billion ≈ $170.85 Million |
CN¥91.43 Million ≈ $13.38 Million |
0.078x | -61.20% |
| 2019-12-31 | CN¥444.63 Million ≈ $65.06 Million |
CN¥89.74 Million ≈ $13.13 Million |
0.202x | +20.24% |
| 2018-12-31 | CN¥389.32 Million ≈ $56.97 Million |
CN¥65.35 Million ≈ $9.56 Million |
0.168x | -30.73% |
| 2017-12-31 | CN¥346.28 Million ≈ $50.67 Million |
CN¥83.92 Million ≈ $12.28 Million |
0.242x | +79.32% |
| 2016-12-31 | CN¥320.94 Million ≈ $46.96 Million |
CN¥43.37 Million ≈ $6.35 Million |
0.135x | +4270.59% |
| 2013-12-31 | CN¥215.00 Million ≈ $31.46 Million |
CN¥-696.70K ≈ $-101.95K |
-0.003x | -111.61% |
| 2012-12-31 | CN¥173.32 Million ≈ $25.36 Million |
CN¥4.84 Million ≈ $707.67K |
0.028x | +108.80% |
| 2011-12-31 | CN¥48.09 Million ≈ $7.04 Million |
CN¥-15.24 Million ≈ $-2.23 Million |
-0.317x | -- |
About Guangzhou LBP Medicine Science & Technology Co Ltd
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase… Read more